Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Yan, Benedict ^a   Kuick, Chik Hong ^a   Lim, Malcolm ^a   Venkataraman, Kavita ^b   Tennakoon, Chandana ^c   Loh, Eva ^a   Lian, Derrick ^a   Leong, May Ying ^a   Lakshmanan, Manikandan ^d   Tergaonkar, Vinay ^d   Sung, Wing Kin ^c,e   Soh, Shui Yen ^a   Chang, Kenneth T E ^a  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; ION TORRENT PERSONAL GENOME MACHINE SEQUENCING; MAJOR CLINICAL STUDY; MALE; MOUSE; MUTATIONAL ANALYSIS; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION; SANGER SEQUENCING; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHILD; GENETICS; INFANT; METABOLISM; MUTATION; NEWBORN; PRESCHOOL CHILD;

ANIMALS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFANT; INFANT, NEWBORN; MICE; MICE, INBRED BALB C; MUTATION; NEUROBLASTOMA; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84906963499     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106575     Document Type: Article

References (42)

1. Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, et al. (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 14: 472-480.
2. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, et al. (2010) Metaanalysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16: 4353-4362.
3. Duijkers FA, Gaal J, Meijerink JP, Admiraal P, Pieters R, et al. (2012) High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol 180: 1223-1231.
4. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, et al. (2009) Mutationindependent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 69: 7338-7346.
5. Wang M, Zhou C, Sun Q, Cai R, Li Y, et al. (2013) ALK amplification and protein expression predict inferior prognosis in neuroblastomas. Exp Mol Pathol 95: 124-130.
6. Yan B, Lim M, Zhou L, Kuick CH, Leong MY, et al. (2013) Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas. J Clin Pathol 66: 985-991.
7. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930-935.
8. Caren H, Abel F, Kogner P, Martinsson T (2008) High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416: 153-159.
9. Schildhaus HU, Deml KF, Schmitz K, Meiboom M, Binot E, et al. (2013) Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung. Mod Pathol 26: 1468-1477.
10. Chen Y, Takita J, Choi YL, Kato M, Ohira M, et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974.
11. George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978.
12. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970.
13. Hallberg B, Palmer RH (2013) Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 13: 685-700.
14. Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, et al. (2011) Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 3: 108ra114.
15. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, et al. (2012) Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol 30: 1033-1036.
16. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, et al. (2013) ACMG clinical laboratory standards for next-generation sequencing. Genet Med 15: 733-747.
17. McCourt CM, McArt DG, Mills K, Catherwood MA, Maxwell P, et al. (2013) Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One 8: e69604.
18. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, et al. (2013) Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15: 607-622.
19. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, et al. (2012) Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307: 1062-1071.
20. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, et al. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589-593.
21. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, et al. (2013) The genetic landscape of high-risk neuroblastoma. Nat Genet 45: 279-284.
22. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, et al. (2013) Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 45: 12-17.
23. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31: 3997-4013.
24. Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9: 357-359.
25. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res 20: 1297-1303.
26. Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14: 178-192.
27. Ross MG, Russ C, Costello M, Hollinger A, Lennon NJ, et al. (2013) Characterizing and measuring bias in sequence data. Genome Biol 14: R51.
28. Benjamini Y, Speed TP (2012) Summarizing and correcting the GC content bias in high-throughput sequencing. Nucleic Acids Res 40: e72.
29. Okubo J, Takita J, Chen Y, Oki K, Nishimura R, et al. (2012) Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene 31: 4667-4676.
30. Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, et al. (2013) Diagnostic assays for identification of anaplastic lymphoma kinasepositive non-small cell lung cancer. Cancer 119: 1467-1477.
31. Kim H, Yoo SB, Choe JY, Paik JH, Xu X, et al. (2011) Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 6: 1359-1366.
32. Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, et al. (2013) Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 26: 1545-1553.
33. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, et al. (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89: 1394-1404.
34. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16: 1561-1571.
35. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, et al. (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8: 45-51.
36. Li Y, Pan Y, Wang R, Sun Y, Hu H, et al. (2013) ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One 8: e69016.
37. Ying J, Guo L, Qiu T, Shan L, Ling Y, et al. (2013) Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol 24: 2589-2593.
38. Hasan MK, Nafady A, Takatori A, Kishida S, Ohira M, et al. (2013) ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Sci Rep 3: 3450.
39. Huang M, Weiss WA (2013) Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 3: a014415.
40. Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, et al. (2010) A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 63: 839-842.
41. Cazes A, Louis-Brennetot C, Mazot P, Dingli F, Lombard B, et al. (2013) Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. Cancer Res 73: 195-204.
42. Azarova AM, Gautam G, George RE (2011) Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 21: 267-275.